Get started
Author

Felix Unverdorben

Observed names: F. Unverdorben, Unverdorben, Felix
ORCID: 0000-0003-3418-2650
Observed ORCID: 0000-0003-3418-2650
OpenAlex ID: A5015123153
Pharmacokinetic properties of IgG and various Fc fusion proteins in mice
2015 · Felix Unverdorben, Fabian Richter, et al. · mAbs · 119
PDF
Plasma Half-life Extension of Small Recombinant Antibodies by Fusion to Immunoglobulin-binding Domains
2011 · Meike Hutt, Aline Färber-Schwarz, et al. · Journal of Biological Chemistry · 79
Regulation of ICAM-1 in Cells of the Monocyte/Macrophage System in Microgravity
2015 · Katrin Paulsen, Svantje Tauber, et al. · BioMed Research International · 64
PDF
Quantitative immunopeptidomics reveals a tumor stroma–specific target for T cell therapy
2022 · Gloria B. Kim, Jens Fritsche, et al. · Science Translational Medicine · 41
PDF
Half-life extension of a single-chain diabody by fusion to domain B of staphylococcal protein A
2012 · F. Unverdorben, A. Farber-Schwarz, et al. · Protein Engineering Design and Selection · 29
Identification of Reference Genes in Human Myelomonocytic Cells for Gene Expression Studies in Altered Gravity
2015 · Cora S. Thiel, Swantje Hauschild, et al. · BioMed Research International · 23
PDF
A Fab-Selective Immunoglobulin-Binding Domain from Streptococcal Protein G with Improved Half-Life Extension Properties
2015 · Felix Unverdorben, Meike Hutt, et al. · PLoS ONE · 22
PDF
Mammalian Display Platform for the Maturation of Bispecific TCR-Based Molecules
2022 · Janine Dilchert, Martin Hofmann, et al. · Antibodies · 14
PDF
An anti-TNFR1 scFv-HSA fusion protein as selective antagonist of TNF action
2013 · V. Berger, F. Richter, et al. · Protein Engineering Design and Selection · 11
Expression and Purification of Recombinant Antibody Formats and Antibody Fusion Proteins
2014 · Martin Siegemund, Fabian Richter, et al. · Methods in molecular biology · 10
Effective Targeting of PRAME-Positive Tumors with Bispecific T Cell-Engaging Receptor (TCER®) Molecules
2019 · Sebastian Bunk, Martin Hofmann, et al. · Blood · 7
IMA402, an Off-the-Shelf, Next-Generation TCR Bispecific (TCER®) for Efficiently Targeting an HLA-Presented Peptide from the Pan-Cancer Antigen PRAME
2022 · Sebastian Bunk, Martin Hofmann, et al. · Blood · 4
753P Targeting solid tumors with IMA402, a next-generation bispecific T cell engaging receptor against PRAME
2022 · S. Missel, S. Bunk, et al. · Annals of Oncology · 4
1319 Next-generation TCR bispecifics (TCER®) targeting peptide-HLA antigens for the treatment of patients with solid tumors
2022 · Sebastian Bunk, Martin Hofmann, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
Abstract 2789: Development of highly potent T-cell receptor bispecifics with picomolar activity against tumor-specific HLA ligands
2018 · Sebastian Bunk, Martin Hofmann, et al. · Cancer Research · 2
Generation of a highly versatile TCR bispecific scaffold optimized for targeting tumor-specific peptide-HLA antigens
2026 · Martin Hofmann, Felix Unverdorben, et al. · mAbs
PDF
Immunoglobulin-based strategies for half-life extension of recombinant proteins
2015 · Unverdorben, Felix · OPUS Publication Server of the University of Stuttgart (University of Stuttgart)
PDF
Works count: 17
Citation count: 431
H-index: 10
I10-index: 10
Year
Topic
Type